Sorrento Therapeutics Subsidiary Receives FDA Approval for Non-Opiod Ztlido

published 10:53 pm ET February 28th, 2018

On February 28, Sorrento Therapeutics (SRNE) Subsidiary, Scilex, received FDA approval for non-opiod Ztlido. The drug is a lidocaine topical system used to treat pain. Sorrento hopes to have it commercially available to patients later this year.

 

Rocket Tickers received the news and sent an alert to subscribers at 2:11 pm. The next trade took place for $8.95 at 2:45 pm. After a brief fade, the price pushed higher until the close at $9.95.

Visit the Knowledge Center for more information about clinical trials and how to trade them.

Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.

Subscribe here if you would like to start receiving these signals in real-time and start trading!